AQR Capital Management LLC Lowers Stock Holdings in Artivion, Inc. (NYSE:AORT)

AQR Capital Management LLC trimmed its position in Artivion, Inc. (NYSE:AORT) by 20.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,489 shares of the company’s stock after selling 5,640 shares during the quarter. AQR Capital Management LLC’s holdings in Artivion were worth $551,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in shares of Artivion in the second quarter worth about $366,000. Public Sector Pension Investment Board lifted its holdings in shares of Artivion by 7.8% in the second quarter. Public Sector Pension Investment Board now owns 87,273 shares of the company’s stock worth $2,239,000 after buying an additional 6,344 shares in the last quarter. RW Investment Management LLC purchased a new stake in shares of Artivion in the second quarter worth about $219,000. Intech Investment Management LLC bought a new position in shares of Artivion in the second quarter worth approximately $253,000. Finally, XTX Topco Ltd bought a new position in shares of Artivion in the second quarter worth approximately $331,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the sale, the director now owns 34,159 shares in the company, valued at $853,633.41. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total transaction of $242,627.91. Following the sale, the director now owns 34,159 shares in the company, valued at approximately $853,633.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 2,383 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $25.76, for a total transaction of $61,386.08. Following the completion of the transaction, the senior vice president now owns 165,099 shares in the company, valued at approximately $4,252,950.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,109 shares of company stock valued at $951,935 over the last three months. 8.10% of the stock is owned by company insiders.

Artivion Trading Up 1.0 %

AORT stock opened at $26.19 on Tuesday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. Artivion, Inc. has a one year low of $12.16 and a one year high of $29.24. The company’s 50 day moving average price is $25.58 and its two-hundred day moving average price is $24.31. The company has a market capitalization of $1.09 billion, a PE ratio of -109.92 and a beta of 1.74.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. The company had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. As a group, analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AORT. Stifel Nicolaus upped their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective on shares of Artivion in a research report on Friday, September 27th. Lake Street Capital upped their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Finally, Oppenheimer upped their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.